NovaBay Pharmaceuticals与吴大学合作，教育眼科护理专业人员使用羊膜-动脉网

NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes

businesswire 等信源发布 2023-12-06 18:50



可切换为仅中文







EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes. A free webinar is being held Thursday, December 7, 2023 from 5:30-6:30 pm Pacific time, and eyecare professionals can register here.

加利福尼亚州埃默里维尔（商业新闻短讯）--NovaBay Pharmaceuticals，Inc.（纽约证券交易所美国代码：NBY）宣布与吴大学合作，支持眼科专业人员使用羊膜的教育。太平洋时间2023年12月7日（星期四）下午5:30-6:30举行免费网络研讨会，眼科专业人士可以在此注册。

In September 2023 NovaBay commercially launched its prescription amniotic membrane product Avenova® Allograft, which is intended for use as a protective covering during the repair of ocular surfaces..

2023年9月，NovaBay商业推出了其处方羊膜产品Avenova®同种异体移植物，该产品用于眼表修复过程中的保护层。。

The optometric continuing education (CE)-credit webinar will feature host Dr. Stephanie Woo, moderator Dr. Elise Kramer, and sponsor presenter Dr. Maria Sampalis discussing the role of amniotic membranes in treating a variety of ocular surface conditions, candidate selection, and billing and coding.

验光继续教育（CE）-学分网络研讨会将由主持人Stephanie Woo博士，主持人Elise Kramer博士和赞助商主持人Maria Sampalis博士主持，讨论羊膜在治疗各种眼表疾病，候选人选择以及计费和编码中的作用。

The webinar will also feature case reports demonstrating the healing power of amniotic membranes. Woo University is a non-profit organization committed to providing high-quality continuing education to eyecare professionals around the world..

网络研讨会还将以病例报告为特色，展示羊膜的愈合能力。吴大学是一家非营利性组织，致力于为世界各地的眼科专业人员提供高质量的继续教育。。

“This webinar is intended to provide optometrists with useful information about how to incorporate amniotic membranes into their practices while providing NovaBay with the opportunity to create further awareness of our high-quality product among our targeted customer base,” said Justin Hall, CEO and General Counsel of NovaBay.

NovaBay首席执行官兼总法律顾问贾斯汀·霍尔（JustinHall）表示：“本次网络研讨会旨在为验光师提供有关如何将羊膜纳入其实践的有用信息，同时为NovaBay提供机会，让我们的目标客户群进一步了解我们的高质量产品。”。

“This event is just one of a number of outreach programs aimed at educating eyecare specialists on the clinical benefits of the Avenova Allograft, which we believe will be important in positioning and differentiating our product among prospective customers.”.

“本次活动只是旨在教育眼科专家了解Avenova同种异体移植的临床益处的众多推广计划之一，我们认为这对于在潜在客户中定位和区分我们的产品非常重要。”。

The Avenova® Allograft provides a protective environment or covering for repair of the cornea and conjunctiva, helping ocular surface to return to a healthier state. It is the only optic allograft manufactured using the patented six-step BioREtain® process that preserves the natural integrity of the placental tissue.

Avenova®同种异体移植物为角膜和结膜的修复提供了保护性环境或覆盖物，有助于眼表恢复到更健康的状态。它是唯一一种使用专利的六步法BioREtain®工艺制造的光学同种异体移植物，可保持胎盘组织的自然完整性。

The product consists only of the amnion layer of the placental membrane and measures between 20-50 microns thick, making it ideal for delicate ophthalmic applications. Avenova Allograft is available in 8mm, 10mm and 12mm diameter sizes. The Avenova Allograft competes in a global market estimated at $403.6 million in 2022, which is expected to grow at 9.8% per year between 2023-2030.

该产品仅由胎盘膜的羊膜层组成，厚度在20-50微米之间，非常适合精细的眼科应用。Avenova同种异体移植物有8mm，10mm和12mm直径。2022年，Avenova同种异体移植物在全球市场上的竞争价值估计为4.036亿美元，预计2023年至2030年间每年将以9.8%的速度增长。

Eyecare professionals can order Avenova Allograft directly on Avenova.com..

眼科专业人士可以直接在Avenova.com上订购Avenova同种异体移植物。。

In addition to the allograft product, NovaBay’s Avenova suite of products include Avenova antimicrobial lid and lash spray, specially designed dry wipes, lubricating eye drops, a warm eye compress, oral supplements and the i-Chek mirror to monitor physical eyelid health.

除了同种异体移植产品外，NovaBay的Avenova系列产品还包括Avenova抗菌眼睑和睫毛喷雾剂、专门设计的干湿巾、润滑滴眼液、温热眼压、口服补充剂和i-Chek镜子，以监测眼睑的健康状况。

About NovaBay Pharmaceuticals, Inc.:

关于NovaBay Pharmaceuticals，Inc.：

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare, skincare and wound care products. NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to consumers through online distribution channels such as Amazon.

NovaBay Pharmaceuticals，Inc.开发和销售科学创造和临床验证的眼部护理、皮肤护理和伤口护理产品。NovaBay的领先产品Avenova®抗菌眼睑和睫毛液通常由眼科专业人士开具，用于治疗睑缘炎和干眼症，也可通过亚马逊等在线分销渠道直接向消费者提供。

DERMAdoctor® offers more than 30 dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S.

DERMAdoctor®通过DERMAdoctor网站、知名传统和数字美容零售商以及国际分销商提供30多种皮肤科医生开发的护肤产品。NovaBay还生产和销售有效、温和且无刺激性的伤口护理产品。PhaseOne®品牌通过美国的商业合作伙伴进行分销。

for professional use only, and the NeutroPhase® brand is distributed in China by China Pioneer Pharma Holdings, Limited. More information about NovaBay is available here..

NeutroPhase®品牌仅限专业使用，由中国先锋制药控股有限公司在中国经销。有关NovaBay的更多信息，请点击此处。。

Forward-Looking Statements

前瞻性声明

Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc.

除历史信息外，本新闻稿中所述事项可能是1995年《私人证券诉讼改革法案》中“安全港”条款所指的前瞻性事项，包括关于NovaBay Pharmaceuticals，Inc.商业进展和未来财务业绩的声明。

This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current partnerships, marketing efforts, and any future revenue that may result from such partnerships and related marketing initiatives, as well as generally the Company’s expected future financial results.

本版本包含基于管理层当前期望、假设、估计、预测和信念的前瞻性声明。这些报表包括但不限于有关我们的业务战略、当前合作伙伴关系、营销努力以及此类合作伙伴关系和相关营销举措可能产生的任何未来收入的报表，以及公司预期的未来财务业绩。

These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company’s cash needs.

这些声明涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致实际结果或成就与前瞻性声明中表达或暗示的结果或成就存在重大差异和不利影响。可能导致或促成这种差异的因素包括但不限于与我们产品的潜在市场规模有关的风险和不确定性，公司产品的可用市场可能不会像预期的那样大，公司产品无法渗透一个或多个目标市场，收入不足以满足公司的现金需求。

Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially un.

与NovaBay业务相关的其他风险，包括可能导致结果与本新闻稿中前瞻性声明中预测的结果产生重大差异的风险，详见NovaBay最新的10-Q/K表格备案和s-1表格备案登记声明，特别是联合国。

Socialize and Stay Informed on NovaBay’s Progress

社交并随时了解NovaBay的进展

Like us on Facebook

就像我们在脸书上

在推特上关注我们

Connect with NovaBay on LinkedIn

在LinkedIn上与NovaBay连接

Visit NovaBay’s Website

访问NovaBay的网站

Avenova Purchasing Information

Avenova采购信息